Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(11):828-829; doi:10.1093/jnci/djk222
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Azzoli, C. G.
Right arrow Articles by Pfister, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Azzoli, C. G.
Right arrow Articles by Pfister, D. G.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

EDITORIALS

Cisplatin Versus Carboplatin for Patients With Metastatic Non–Small-Cell Lung Cancer—An Old Rivalry Renewed

Christopher G. Azzoli, Mark G. Kris, David G. Pfister

Affiliation of authors: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

Correspondence to: Christopher G. Azzoli, MD, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Box 215, New York, NY 10021 (e-mail: azzolic@mskcc.org).

The first 10% of the full text of this article appears below.

Oncologists in the United States have embraced carboplatin as their favorite platinum drug for the first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC). Two North American phase III trials have compared carboplatin plus paclitaxel with cisplatin-based combinations and demonstrated similar efficacy but lower rates of nausea, leukopenia, and nephrotoxicity with the use of carboplatin (1,2). Carboplatin and either paclitaxel, docetaxel, or gemcitabine have since become the three most commonly used drug regimens in the United States for NSCLC. Furthermore, carboplatin plus paclitaxel was chosen as the standard treatment arm for the Eastern Cooperative Oncology Group (ECOG) study 4599, the randomized trial that demonstrated a statistically significant improvement in response rate and survival when bevacizumab was added to the doublet as first-line treatment of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
Andrea Ardizzoni, Luca Boni, Marcello Tiseo, Frank V. Fossella, Joan H. Schiller, Marianne Paesmans, Davorin Radosavljevic, Adriano Paccagnella, Petr Zatloukal, Paola Mazzanti, Donald Bisset, and Rafael Rosell
J Natl Cancer Inst 2007 99: 847-857. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 825. [Extract] [Full Text] [PDF]

Press Release: Cisplatin is More Effective than Carboplatin for Treating Non–Small-Cell Lung Cancer
Liz Savage
J Natl Cancer Inst 2007 99: 825. [Extract] [Full Text]